EYEG Stock Skyrockets On Eye Drop Trial Data

The stock is eyeing its best day in nearly three years

by Lillian Currens

Published on Nov 22, 2019 at 9:51 AM

The shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) are surging this morning, just after the drugmaker said its experimental Ocular Bandage Gel (OBG) eye drop showed greater improvement in patients with eye wounds than those met with standard care.

The firm said it will submit the treatment for a marketing application by the first half of 2020. In response, EYEG is up 83.1% at $8.82, set for its biggest one-day percentage gain in nearly three years. 

Prior to today, EYEG was attempting to rally off its late-August record low of $2.25. The security had doubled off this bottom through last night's close, but was running into pressure at the 320-day moving average, and was suffering from a 31.3% year-to-date deficit. Today, however, EYEG has sliced through this trendline and swung into the green for 2019, trading directly below its Jan. 15 annual peak of $8.83.

A Schaeffer's exclusive


Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

3 Easy Ways to Play Options for Income
Trading options is often scary... but it doesn't have to be!
Video Game Makers ATVI, EA Receive Price-Target Raises
Both stocks have been strong in recent months
Call Traders Blast Delphi Technologies After BorgWarner Buyout
DLPH is on track for its best day ever
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.